Low Risk of Failing Direct-Acting Antivirals in People With Human Immunodeficiency Virus/Hepatitis C Virus From Sub-Saharan Africa or Southeastern Asia: A European Cross-Sectional Study

Cas Isfordink, Anders Boyd, Amanda Mocroft, Katharina Kusejko, Colette Smit, Stephane de Wit, Tabitha Mahungu, Karolin Falconer, Gilles Wandeler, Matthias Cavassini, Marcel Stöckle, Janke Schinkel, Andri Rauch, Lars Peters, Marc van der Valk*, for EuroSIDA, the Swiss HIV Cohort Study, and the ATHENA Observational Cohort

*Corresponding author af dette arbejde

Abstract

Background: Several studies have reported suboptimal efficacy of direct-acting antivirals (DAAs) to treat hepatitis C virus (HCV) subtypes endemic to sub-Saharan Africa (SSA) and Southeastern Asia (SEA). The extent of this issue in individuals with human immunodeficiency virus (HIV)/HCV from SSA or SEA residing in Europe is unknown.

Methods: We retrospectively analyzed data from several prospective European cohorts of people living with HIV. We included individuals with HIV/HCV who originated from SSA or SEA, were treated with interferon-free DAAs, and had an available HCV RNA result ≥12 weeks after the end of treatment. The primary outcome was sustained virological response at least 12 weeks after the end of treatment (SVR12).

Results: Of the 3293 individuals with HIV/HCV treated with DAA and with available SVR12 data, 142 were from SSA (n = 64) and SEA (n = 78). SVR12 was achieved by 60 (94% [95% confidence interval {CI}, 86%-98%]) individuals from SSA and 76 (97% [95% CI, 92%-99%]) from SEA. The genotypes of the 6 individuals failing DAA treatment were 2, 3a, 3h, 4a, 4c, and 6j. For 2 of the 4 unsuccessfully treated individuals with available sequence data at treatment failure, NS5A resistance-associated substitutions were present (30R/93S in an individual with genotype 4c and 31M in an individual with genotype 6j).

Conclusions: SVR12 rates were high in individuals with HIV/HCV residing in Europe and originating from regions where intrinsically NS5A-resistant HCV strains are endemic. HCV elimination for this population in Europe is unlikely to be hampered by suboptimal DAA efficacy.

OriginalsprogEngelsk
Artikelnummerofac508
TidsskriftOpen Forum Infectious Diseases
Vol/bind9
Udgave nummer10
ISSN2328-8957
DOI
StatusUdgivet - okt. 2022

Fingeraftryk

Dyk ned i forskningsemnerne om 'Low Risk of Failing Direct-Acting Antivirals in People With Human Immunodeficiency Virus/Hepatitis C Virus From Sub-Saharan Africa or Southeastern Asia: A European Cross-Sectional Study'. Sammen danner de et unikt fingeraftryk.

Citationsformater